![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZYG11A |
Gene summary for ZYG11A |
![]() |
Gene information | Species | Human | Gene symbol | ZYG11A | Gene ID | 440590 |
Gene name | zyg-11 family member A, cell cycle regulator | |
Gene Alias | ZYG11 | |
Cytomap | 1p32.3 | |
Gene Type | protein-coding | GO ID | GO:0000151 | UniProtAcc | Q6WRX3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
440590 | ZYG11A | HCC1 | Human | Liver | HCC | 1.21e-04 | 7.17e-01 | 0.5336 |
440590 | ZYG11A | HCC2 | Human | Liver | HCC | 1.76e-07 | 1.06e+00 | 0.5341 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZYG11A | SNV | Missense_Mutation | c.1483N>T | p.Ala495Ser | p.A495S | Q6WRX3 | protein_coding | deleterious(0.02) | possibly_damaging(0.499) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZYG11A | SNV | Missense_Mutation | novel | c.1781C>A | p.Ser594Tyr | p.S594Y | Q6WRX3 | protein_coding | tolerated(0.1) | possibly_damaging(0.712) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
ZYG11A | SNV | Missense_Mutation | c.235C>A | p.Leu79Ile | p.L79I | Q6WRX3 | protein_coding | deleterious(0) | possibly_damaging(0.577) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
ZYG11A | SNV | Missense_Mutation | rs770389974 | c.220G>T | p.Val74Leu | p.V74L | Q6WRX3 | protein_coding | tolerated(0.96) | benign(0.005) | TCGA-B5-A0K2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Hormone Therapy | megace | SD |
ZYG11A | SNV | Missense_Mutation | c.1813A>G | p.Ile605Val | p.I605V | Q6WRX3 | protein_coding | tolerated(0.36) | benign(0.012) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZYG11A | SNV | Missense_Mutation | novel | c.1335N>T | p.Lys445Asn | p.K445N | Q6WRX3 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZYG11A | SNV | Missense_Mutation | novel | c.1569N>T | p.Lys523Asn | p.K523N | Q6WRX3 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZYG11A | SNV | Missense_Mutation | rs774430415 | c.1216G>A | p.Ala406Thr | p.A406T | Q6WRX3 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZYG11A | SNV | Missense_Mutation | novel | c.967N>A | p.Ala323Thr | p.A323T | Q6WRX3 | protein_coding | tolerated(0.06) | possibly_damaging(0.835) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZYG11A | SNV | Missense_Mutation | novel | c.1795N>A | p.Glu599Lys | p.E599K | Q6WRX3 | protein_coding | tolerated(0.48) | benign(0.013) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |